Всегда ли тромбоцитопения – проблема гематолога? Лечебно-диагностические алгоритмы в практике терапевта и гастроэнтеролога


И.Г. Бакулин, Л.Н. Белоусова, Л.С. Евдокимова

ФГБОУ ВО «СЗГМУ им. И.И. Мечникова» Минздрава России, Санкт-Петербург
За последние годы получено достаточно доказательных данных о развитии тромбоцитопении при различных патологических состояниях, что указывает на необходимость знаний и опыта врачей различных клинических специальностей при проведении лечебно-диагностических мероприятий. В статье рассматриваются механизмы развития тромбоцитопении. Приводятся клинический алгоритм и лабораторно-инструментальные методы исследования, позволяющие выяснять генез тромбоцитопении. Особое внимание уделяется механизмам развития тромбоцитопении при заболеваниях пищеварительной системы.

Литература


1. Provan D., Stasi R., Newland A.S., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.

2. Бакулин И.Г., Шарабанов А.С., Моляренко Е.В., Яковлева Е.В. Тромбоцитопении у больных хроническим гепатитом С. Экспериментальная и клиническая гастроэнтерология. 2010;5:52–60.

3. George J.N. Platelets. Lancet. 2000;355:1531–39.

4. Национальные клинические рекомендации по диагностике и лечению идиопатической тромбоцитопенической пурпуры (первичной иммунной тромбоцитопении) у взрослых. М., 2016. 55 с.

5. Луговская С.А., Морозова В.Т., Почтарь М.Е., Долгов В.В. Лабораторная гематология. М., 2006. 223 с.

6. Gasbarrini A., Franceschi F., Tartaglione R., Landolfi R., Pola P., Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352:878.

7. Ko G.H., Part H.B., Shin M.K., et al. Monoclonal antibodies against Helicobacter pylori cross-react with human tissue. Helicobacter. 1997;4:210–15.

8. Nagachima R., Maeda K., Yuda F., Kudo K., Saitoh M.,Takahashi T. Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch. 1997;431:235–39.

9. Machet L., Vaillant L., Machet M.C., Buchler M., Lorette G. Schonlein-Henoch purpura associated with gastric Helicobacter pylori infection. Dermatology. 1997;194:86.

10. Scandellari R., Allemand E., Vettore S., Plebani M., Randi M.L., Fabris F. Platelet response to Helicobacter pylori eradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies. Blood Coagul. Fibrinolysis. 2009;20:108–13.

11. Figura N., Franceschi F., Santucci A., Bernardini G., Gasbarrini G., Gasbarrini A. Extragastric Manifestations of Helicobacter pylori Infection. Helicobacter. 2010;15(1):60–8.

12. Michel M., Khellaf M., Desforges L., Lee K., Schaeffer A., Godeau B., Bierling P.. Autoimmune thrombocytopenic Purpura and Helicobacter pylori infection. Arch. Intern. Med. 2002;162:1033–36.

13. Takahashi T., Yujiri T., Shinohara K., Inoue Y., Sato Y., Fujii Y., Okubo M., Zaitsu Y., Ariyoshi K., Nakamura Y., et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 2004;124:91–6.

14. Bai Y., Wang Z., Bai X., Yu Z., Cao L., Zhang W., et al. Cross-reaction of antibody against Helicobacter pyloriurease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int. J. Hematol. 2009;89:142–49.

15. Yamanishi S., Iizumi T., Watanabe E., Shimizu M., Kamiya S., Nagata K., Kumagai Y., Fukunaga Y., Takahashi H. Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect. Immun. 2006;74:248–56.

16. Pellicano R., Touscoz G.A., Smedile A., Berrutti M., Saracco G., Repici A., Ponzetto A., Rizzetto M. Prevalence of non-organ-specific autoantibodies in patients suffering from duodenal ulcer with and without Helicobacter pylori infection. Dig. Dis. Sci. 2004;49:395–98.

17. Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J. Gastroenterol. 2014;20:714–23.

18. Asahi A., Kuwana M., Suzuki H., Hibi T., Kawakami Y., Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica. 2006;91:1436–37.

19. Wu Z., Zhou J., Prsoon P., Wei X., Liu X., Peng B. Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals. Int. J. Hematol. 2012;96:588–93.

20. Fujimura K. Kuwana M., Kurata Y., Imamura M., Harada H., Sakamaki H., Teramura M., Koda K., Nomura S., Sugihara S., et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int. J. Hematol. 2005;81:162–68.

21. Veneri D., De Matteis G., Solero P., Federici F., Zanuso C., Guizzardi E., Arena S., Gaio M., Pontiero P., Ricetti M.M., et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets. 2005;16:307–11.

22. Satoh T., Pandey J.P., Okazaki Y., Asahi A., Kawakami Y., Ikeda Y., Kuwana M. Single nucleotide polymorphism of interleukin-1beta associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens. 2009;73:353–57.

23. Hashino S., Mori A., Suzuki S., Izumiyama K., Kahata K., Yonezumi M., Chiba K., Kondo T., Ota S., Toyashima N., et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int. J. Hematol. 2003;77:188–91.

24. Nomura S., Inami N., Kanazawa S. The effects of Helicobacter pylori eradication on chemokine production in patients with immune thrombocytopenic purpura. Eur. J. Haematol. 2004;72:304–5.

25. Stasi R., Rossi Z., Stipa E., Amadori S., Newland A.C., Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am. J. Med. 2005;118:414–419.

26. Kodama M., Kitadai Y., Ito M., Kai H., Masuda H., Tanaka S., Yoshihara M., Fujimura K., Chayama K.. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter. 2007;12:36–42.

27. Ando K., Shimamoto T., Tauchi T., Ito Y., Kuriyama Y., Gotoh A., Miyazawa K., Kimura Y., Kawai T., Ohyashiki K. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int. J. Hematol. 2003;77:239–44.

28. Inaba T., Mizuno M., Take S., Suwaki K., Honda T., Kawai K., Fujita M., Tamura T., Yokota K., Oguma K., et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur. J. Clin. Invest. 2005;35:214–19.

29. Emilia G., Luppi M., Zucchini P., Morselli M., Potenza L., Forghieri F., Volzone F., Jovic G., Leonardi G., Donelli A., et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007;110:3833–41.

30. Payandeh M., Raeisi D., Sohrabi N., Zare M.E., Kansestani A.N., Keshavarz N., Gholami S., Hashemian A.H. Poor platelet count response to Helicobacter pylori eradication in patients with severe idiopathic thrombocytopenic purpura. Int. J. Hematol. Oncol. Stem. Cell. Res. 2013;7:9–14.

31. Sato R., Murakami K., Watanabe K., Okimoto T., Miyajima H., Ogata M., Ohtsuka E., Kodama M., Saburi Y., Fujioka T., et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch. Intern. Med. 2004;164:1904–907.

32. Suzuki T., Matsushima M., Shirakura K., Koike J., Masui A., Takagi A., Shirasugi Y., Ogawa Y., Shirai T., Mine T. Association of inflammatory cytokine gene polymorphisms with platelet recovery in idiopathic thrombocytopenic purpura patients after the eradication of Helicobacter pylori. Digestion. 2008;77:73–8.

33. Satoh T., Miyazaki K., Shimohira A., Amano N., Okazaki Y., Nishimoto T., Akahoshi T., Munekata S., Kanoh Y., Ikeda Y., et al. Fcγ receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia. Blood. 2013;122:1991–92.

34. Sato R., Murakami K., Okimoto T., Watanabe K., Kodama M., Fujioka T. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J. Gastroenterol. 2011;46:991–97.

35. Samson A.D., Schipperus M.R., Langers A.M., Dekkers O.M. Helicobacter pylori infection is not correlated with subclinical thrombocytopenia: A cross-sectional study. Platelets. 2014;25:221–23.

36. Gan G.G., Norfaizal A.L., Bee P.C., Chin E.F., Habibah A.H., Goh K.L. Helicobacter pylori infection in chronic immune thrombocytopenic purpura patients in Malaysia. Med. J. Malaysia. 2013;68:231–33.

37. Peck-Radosavljevic, M. Thrombocytopenia in chronic liver disease. Liver International. 2017;37:778–93.

38. Wai C.-T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S.-F. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C. Hepatology. 2003;2(38):518–36.

39. Qamar A.A., Grace N.D., Groszmann R.J., et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin. Gastroenterol. Hepatol. 2009;7:689–95.

40. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J. Clin. Invest. 1966;45:645–57.

41. Borel Rinkes I.H., Van der Hoop A.G., Hesselink E.J., et al. Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology. 1991;100:1126–28.

42. Бакулин И.Г., Пузин С.Н., Сандлер Ю.Г. и др. Медико-социальное значение тромбоцитопении у больных хроническими заболеваниями печени. Вестник всероссийского общества специалистов по медико-социальной экспертизе, реабилитации и реабилитационной индустрии. 2011;2:73–80.

43. Mitchell O., Feldman D.M., Diakow M., Sigal S.H. The pathophysiology of thrombocytopenia in chronic liver disease. Hepatic Medicine: Evidence and Research. 2016;8:39–50.

44. Lindenbaum J., Lieber C.S. Hematologic effects of alcohol in man in the absence of nutritional deficiency. N. Engl. J. Med. 1969;281(7):333–38.

45. Ballard H.S. Hematological complications of alcoholism. Alcohol. Clin. Exp. Res. 1989;13:706–20.

46. Yamane A., Nakamura T., Suzuki H., et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008;112(3):542–50.

47. Pereira J., Accatino L., Alfaro J., et al. Platelet autoantibodies in patients with chronic liver disease. Am. J. Hematol. 1995;50(3):173–78.

48. Bassendine M.F., Collins J.D., Stephenson J., et al. Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia? Gut. 1985;26(10):1074–79.

49. Nagamine T., Ohtuka T., Takehara K., et al. Thrombocytopenia associated with hepatitis C viral infection. J. Hepatol. 1996;24(2):135–40.

50. Pivetti S., Novarino A., Merico F., Bertero T., Brunetto M.R., Bonino F., Caligaris-Cappio F. High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective disorders. Br. J. Haematol.1996;95:204–11.

51. Pollock J.L. Extrahepatic manifestations of hepatitis C virus infection. Ann. Int. Med.1996;125:345.

52. Pawlotsky J.M., Bouvier M., Fromont P., et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J. Hepatol. 1995;23(6):635–39.

53. Weksler B.B. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment. Pharmacol. Ther. 2007;26(Suppl. 1):13–9.

54. Wang C.S., Yao W.J., Wang S.T., et al. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin. Infect. Dis. 2004;39(6):790–96.

55. Bordin G., Ballare M., Zigrossi P., et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin. Exp. Rheumatol. 1995;13(Suppl. 13):39–43.

56. Garcia-Suarez J., Burgaleta C., Hernanz N., et al. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br. J. Haematol. 2000;110(1):98–103.

57. Mayo M.J. Extrahepatic manifestations of hepatitis C infection. Am. J. Med. Sci. 2003;325(3):135–48.

58. Ramos-Casals М., Zignego А., Ferri С., et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J. Hepatology. 2017;66:1282–99.

59. Hamaia S., Li C., Allain J.P. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood. 2001;98(8):2293–300.

60. Panzer S., Seel E. Is there an increased frequency of autoimmune thrombocytopenia in hepatitis C infection? A review. Wien. Med. Wochenschr. 2003;153(19–20):417–20.

61. Misiani R., Bellavita P., Fenili D., et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann. Intern. Med. 1992;117(7):573–77.


Об авторах / Для корреспонденции


Автор для связи: Л.Н. Белоусова – к.м.н., кафедра пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова» Минздрава России, Санкт-Петербург; e-mail: liya-belousova@yandex.ru


Похожие статьи


Бионика Медиа